Eli Lilly Signs $475M Deal with MeiraGTx for Vision-Restoring Gene Therapy
Eli Lilly partners with MeiraGTx in a $475M deal for a breakthrough gene therapy, AAV-AIPL1, designed to restore vision in children born legally blind.
/ 915 items
#Healthcare↓
MannKind Ends Phase 3 ICoN-1 Trial for Nebulized Clofazimine After Futility Review
MannKind Corporation discontinues its Phase 3 ICoN-1 trial for nebulized clofazimine (MNKD-101) in NTM lung disease after futility analysis shows no efficacy. The company will focus on developing its dry powder version, MNKD-102.
Historic Breakthrough in GIST Treatment: Cogent’s Bezuclastinib Combination Poised to Become New Standard of Care
Cogent Biosciences announced "transformative" success with their experimental drug, bezuclastinib, in combination with sunitinib, significantly delaying disease progression in patients battling advanced GIST (a form of stomach cancer).
Trump's Attack on Health Insurers Sends Stocks Tumbling
Health insurance stocks dropped during pre-market trading after President Trump criticized insurers on social media and proposed providing direct subsidies to consumers instead of ACA tax credits.
FDA Pauses Tenaya TN-201 Gene Therapy Trial for Standardization
The FDA placed a clinical hold on Tenaya’s TN-201 trial for MYBPC3-associated HCM to standardize immunosuppression patient management across sites. No delays expected.
Novo Nordisk Shares Jump 3% After Withdrawing from $10 Billion Metsera Bidding War
Novo Nordisk stock climbed up to 3% after the Danish drugmaker withdrew from its heated bidding war with Pfizer over obesity drug startup Metsera, citing financial discipline concerns.